IM

IM Cannabis Corp.

IMCCHealthcareNASDAQ

Drug Manufacturers - Specialty & Generic · Last scanned Sep 8, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$54.7M
+1.3% YoY
Net Income
-$11.3M
-6.9% YoY
EBITDA
-$6.9M
+14.3% YoY
Free Cash Flow
-$2.1M

Scan Results

Daily timeframe
3 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 RSI OverboughtRSI 79.1, above 70, stock may be overbought
Sep 2 RSI OverboughtRSI 78.6, above 70, stock may be overbought
About IM Cannabis Corp.

IM Cannabis Corp. engages in importation, distribution and sale of medical cannabis products in Israel and Germany. The $1.2M market capitalization puts IMCC squarely in micro-cap range for its industry. It provides medical cannabis dried flowers; and full-spectrum cannabis extracts under the IMC, BLKMT, and LOT420 brands.

Where IMCC stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, IMCC finished 476.92% above its 150-day moving average ($0.52) and 289.61% above its 200-day moving average ($0.77). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is IMCC overbought or oversold?

At the September 3, 2026 close, IMCC's RSI(14) was 79.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.2M
Fwd P/E-1.52
EPS$-76.05
Beta2.10
52W Change-96.3%
Analysis

IM Cannabis Corp. carries $13.8M in total debt against $1.6M in cash reserves — debt is roughly 8.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$2.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has been relatively flat, moving from $54.3M (2022) to $54.7M (2025).

With a beta above 1.5, IMCC tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. IM Cannabis Corp. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for IM Cannabis Corp. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms